Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC
Written by
Cancer Network
Published
0
comments
0
min
Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.